These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29914752)

  • 21. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
    Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
    Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.
    Ankeny JS; Court CM; Hou S; Li Q; Song M; Wu D; Chen JF; Lee T; Lin M; Sho S; Rochefort MM; Girgis MD; Yao J; Wainberg ZA; Muthusamy VR; Watson RR; Donahue TR; Hines OJ; Reber HA; Graeber TG; Tseng HR; Tomlinson JS
    Br J Cancer; 2016 Jun; 114(12):1367-75. PubMed ID: 27300108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.
    Saka B; Balci S; Basturk O; Bagci P; Postlewait LM; Maithel S; Knight J; El-Rayes B; Kooby D; Sarmiento J; Muraki T; Oliva I; Bandyopadhyay S; Akkas G; Goodman M; Reid MD; Krasinskas A; Everett R; Adsay V
    Ann Surg Oncol; 2016 Jun; 23(6):2010-8. PubMed ID: 26832882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survivin expression and serum levels in pancreatic cancer.
    Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
    World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
    Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
    Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
    Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma.
    Satoi S; Yanagimoto H; Yamamoto T; Toyokawa H; Hirooka S; Yamaki S; Opendro SS; Inoue K; Michiura T; Ryota H; Matsui Y; Kon M
    World J Surg Oncol; 2016 Jan; 14(1):14. PubMed ID: 26791083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refined TNM-staging for pancreatic adenocarcinoma - Real progress or much ado about nothing?
    Roalsø M; Aunan JR; Søreide K
    Eur J Surg Oncol; 2020 Aug; 46(8):1554-1557. PubMed ID: 32107094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
    Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
    PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.
    Riva F; Dronov OI; Khomenko DI; Huguet F; Louvet C; Mariani P; Stern MH; Lantz O; Proudhon C; Pierga JY; Bidard FC
    Mol Oncol; 2016 Mar; 10(3):481-93. PubMed ID: 26856794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
    Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
    Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
    Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
    Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
    Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
    Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
    Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
    Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
    Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
    Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.